XVIVO receives Horizon 2020 funding

The European Commission has selected XVIVO Perfusion’s project “Biomarkers for
clinical assessment of lungs intended for transplantation” for funding through
the Research and Innovation Framework Program Horizon 2020.
A total of 2,666 proposals were submitted to the first SME (Small Medium
Enterprises) Instrument Calls within the European Commission´s newly established
Research and Innovation Framework Program Horizon 2020. 155 projects from 21
countries were selected for funding of a phase I feasibility study. Each project
receives €50,000 to perform a feasibility study and to prepare a Phase 2
application, which, if granted, may result in additional funding.

“With a success rate of 6 percent, we are pleased to have been selected in
competition with many other highly qualified companies. The focus is now on
reaching the targets set for phase 1 and on preparing for a clinical trial in
project phase 2,” says Mrs Petra Apell, Regional Manager at XVIVO Perfusion.

The goal of the project is to identify biomarkers and medical device products
that can further improve the evaluation of lungs using Ex Vivo Lung Perfusion
(EVLP). Lung transplantation is the only therapeutic option for selected
patients suffering from end-stage lung diseases. 80 percent of all donated lungs
are not used for transplantation. The main reason is uncertainty regarding the
function and quality of the lung. EVLP is a technique used to assess the quality
of donated lungs prior to transplantation. EVLP could potentially lead to an
increase in the utilization rate of donated lungs from today´s 20 percent to 40
-60 percent. Validated and objective parameters to evaluate lung functions
during EVLP are expected to improve clinical outcomes in lung transplantation
after EVLP.

“We are delighted that the European Commission has decided to support this
project financially. New biomarkers may lead to continued development and
expansion of the organ perfusion market,” says Dr Magnus Nilsson, CEO of XVIVO
Perfusion.

September 19, 2014
Gothenburg
XVIVO Perfusion AB (publ)
Magnus Nilsson
CEO
For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59,
christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the
company’s website, www.xvivoperfusion.com

The information was submitted for publication on September 19, 2014 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker
symbol XVIVO. More information can be found on the website
www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com